Skip to main content

Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders’ Equity Up 12%; $5M Share Repurchase Program Underway

Highest Q2 and H1 revenue in Company history, reflecting strength across all core segments and reaching a new milestone with an adjusted annualized revenue run-rate exceeding $75 million Continued progress toward profitability targets, with adjusted gross profit reaching approximately $7.4 million on an annualized basis, adjusted gross margin expanding 165 basis points to 9.54%, and adjusted EBITDA improving 13.8% Demonstrated operating leverage and disciplined inventory management, with Q2 operating expenses growing at roughly half the rate of revenue and first-half inventory down 21.8% despite nearly 30% revenue growth Strengthened balance sheet, with total liabilities decreasing 13.3% by $6.27 million, stockholders’ equity rising 12.2% to $20.67 million, and the liabilities-to-assets ratio improving by 550 basis points Liquid...

Continue reading

Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth

Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year 502 active customers as of June 30, 2026, reflecting continued commercial momentum across safety-critical industries Company made substantial progress toward FDA clearance and planned market expansion during the year NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the full year ended June 30, 2026, and provided a business update. “Fiscal 2026 was a year of clear, compounding...

Continue reading

Top Wealth Group Holding Limited Announces First Half 2026 Unaudited Financial Results

— First Half Revenue of $6.1 million, increase 48% year-over-year —— First Half Net Profits of $2.8 million, versus Net Profit of $2.4 million last year — HONG KONG, Aug. 19, 2026 (GLOBE NEWSWIRE) — Top Wealth Group Holding Limited (NASDAQ: TWG)(“Top Wealth” or the “Company”), a company specializes in supplying premium-class sturgeon caviar and related products including premium grade wines today announced its unaudited financial results for the six months ended June 30, 2026. First Half 2026 Financial Results Total Revenues Total revenues for the first half 2026 were $6.1 million, representing an increase of 48% from $4.2 million in the same period of 2025. During the period we have continued to expand our wine distribution business as well as laying a solid foundation for our upstream caviar and related...

Continue reading

Havila Shipping ASA: Second quarter 2026 account

Summary Freight revenues amounted to NOK 139.9 million in Q2 2026, a decrease of NOK 25.6 million compared to the corresponding period last year and a decrease of NOK 24.4 million compared to the previous quarter. The average rate of assignments and utilization in this quarter is slightly better than the previous quarter. Operating expenses were NOK 86.4 million in Q2 2026, an increase compared to Q2 2025 of NOK 2.7 million and a decrease compared to previous quarter of NOK 3.4 million. The company had a profit before depreciation and amortisation of NOK 59.4 million in Q2 2026, compared to NOK 91.3 million in Q2 2025.  Value adjustment of the company’s debt was approximately zero in Q2 2026, compared to NOK – 22.3 million in Q2 2025. Profit before tax was NOK – 12.3 million in Q2 2026, compared to NOK 8.7 million in Q2 2025. As...

Continue reading

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion market with substantial unmet need—nebokitug could potentially be the first novel mechanism RA therapy approved in the U.S. since 2012 Scipher’s AI Network Medicine platform identified first-in-class CCL24-blocker nebokitug as the highest ranked clinical-stage candidate for RA, potentially providing additional therapeutic benefit to the two-thirds of RA patients who do not achieve low disease activity or remission with current therapies Nebokitug RA Phase 2 clinical trial expected to begin in H1 2027 and read out in H1 2028, providing a potential key inflection point Combined company is valued at $150 million before concurrent $30 million...

Continue reading

Progressive Reports July 2026 Results

MAYFIELD VILLAGE, OHIO, Aug. 19, 2026 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended July 31, 2026:  July(millions, except per share amounts and ratios; unaudited)   2026       2025     ChangeNet premiums written $ 7,441     $ 7,057     5   %Net premiums earned $ 7,355     $ 6,986     5   %Net income $ 961     $ 1,090     (12 ) %Per share available to common shareholders $ 1.65     $ 1.85     (11 ) %Total pretax net realized gains (losses) on securities $ (47 )   $ 79     (159 ) %Combined ratio   86.8       85.3     1.5   pts.Average diluted equivalent common shares   582.9       588.2     (1 ) %  July 31,(thousands; unaudited) 2026   2025   % ChangePolicies in Force          Personal Lines          Agency – auto 11,282   10,510   7Direct...

Continue reading

H1, 2026 reporting

To Nasdaq OMX Copenhagen A/S Company announcement no. 592 August 19th, 2026 INTERIM REPORT JANUARY 1ST, 2026 – JUNE 30TH, 2026 (H1 2026) The H1 2026 report for the fiscal year was reviewed and approved at the Board of Directors meeting. HighlightsOverall, the H1, 2026 came out weaker than expected and below the performance of H1, 2025. The topline and in part the bottom-line were negatively impacted by customers delaying pickup of equipment equal to postponed revenue of DKK 7,6 million. The postponement to H2, 2026 lowered the EBITDA and Profit before tax in H1, 2026 by DKK 2,3 million and increased inventories by June 30th, 2026.The revenue for H1 2026 amounted to DKK 67,0 million (H1 2025: DKK 74,5 million).The gross profit amounted to DKK 18,2 million in H1 2026 (H1 2025: DKK 19,6 million), the gross profit margin was 27,2%...

Continue reading

Antalpha Reports Second Quarter 2026 Results

SINGAPORE, Aug. 19, 2026 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (NASDAQ: ANTA) (“Antalpha” or the “Company”) today announced its unaudited financial results for the second quarter ended June 30, 2026. “During the second quarter, we executed across our financing, technology and risk management businesses,” said Paul Liang, Chief Financial Officer of Antalpha. “As financing activity moderated during the quarter, we were selective in deploying capital by prioritizing portfolio quality and long-term client relationships while improving funding efficiency. Antalpha Prime, our flagship financing platform and primary revenue and earnings contributor, delivered operating profitability while maintaining our record of zero principal loss since inception, demonstrating the strength of our underwriting...

Continue reading

Record high second quarter revenue driven by volume increases

Report on first half of 2026for ROCKWOOL A/SRelease no. 22 – 2026to Nasdaq Copenhagen 19 August 2026 Record high second quarter revenue driven by volume increases Highlights1Revenue in H1 2026 reached 1,906 MEUR, delivering growth of six percent in local currencies and five percent in reported figures compared to last year. Q2 2026 delivered strong 10 percent revenue growth in both local currencies and reported figures compared to last year with a record high revenue of 1,000 MEUR. Revenue growth was driven by higher volumes, including market share gains in flat roof projects, supported by narrowing pricing gaps to competing insulation materials. EBITDA in H1 2026 reached 395 MEUR, with a solid 20.7 percent EBITDA margin amid global market uncertainty. Although Q2 2026 was affected by rising energy and transport costs, EBITDA continued...

Continue reading

SQM Reports Earnings for the Six Months Ended June 30, 2026

HighlightsSQM reported total revenues for the six months ended June 30, 2026 of US$4,228.5 million compared to total revenues of US$2,079.3 million for the same period last year.Net income for the six months ended June 30, 2026 of US$1,024.7 million or US$3.59 per share, compared to US$225.9 million or US$0.79 per share for the same period last year.In lithium: record-high quarterly sales volumes surpassing 84 thousand metric tons of Lithium Carbonate Equivalent (LCE).In Iodine: record-high sales price and record quarterly revenue.In Specialty Plant Nutrition: strong sales volumes and solid sales price.During the first half of 2026, SQM and its subsidiaries accrued over US$1.6 billion in payments to the Chilean State.i SQM will hold a conference call to discuss these results on Wednesday,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.